Literature DB >> 12865388

Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.

K Sato1, H Tomioka, C Sano, T Shimizu, K Sano, K Ogasawara, S Cai, T Kamei.   

Abstract

Mycobacterium tuberculosis (MTB) is capable of invading not only macrophages (Mphis) but also type II pneumocytes. In this study, we compared the antimicrobial activities of fluoroquinolones, including gatifloxacin, sitafloxacin and levofloxacin, against the MTB replication in the Mono Mac 6 human Mphi cell line (MM6-Mphis) and the A-549 human type II alveolar epithelial cell line (A-549 cells). When test quinolones were added at the MIC (0.125, 0.06 and 0.25 mg/l for gatifloxacin, sitafloxacin and levofloxacin, respectively) to the culture media of MTB-infected cells, these drugs exerted growth-inhibitory activity against intracellular organisms in the order of sitafloxacin > gatifloxacin > levofloxacin. On the other hand, when test quinolones were added at Cmax in the blood (1.7, 1.0 and 2.0 mg/l for gatifloxacin, sitafloxacin and levofloxacin, respectively), these drugs exhibited bactericidal activity against intracellular MTB in the order of gatifloxacin > sitafloxacin > or = levofloxacin. In addition, when test drugs were added at 1/8 C(max) to 1/2 C(max), the efficacy was in the order of sitafloxacin > gatifloxacin > levofloxacin. Thus, it appears that the MIC values of fluoroquinolones are not always predictive of their antimicrobial activity against intracellular MTB. In this context, it was also found that intracellular uptake of these quinolones by MM6-Mphis and A-549 cells was in the order of sitafloxacin > gatifloxacin > levofloxacin. This implies that the cellular permeability of these quinolones is an important factor that determines their efficacy to eliminate intracellular MTB organisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12865388     DOI: 10.1093/jac/dkg343

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Comparative study for the virulence of Mycobacterium avium isolates from patients with nodular-bronchiectasis- and cavitary-type diseases.

Authors:  Y Tatano; K Yasumoto; T Shimizu; C Sano; K Sato; S Yano; H Takeyama; H Tomioka
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-04       Impact factor: 3.267

2.  In Vitro Activity and MIC of Sitafloxacin against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis Isolated in Thailand.

Authors:  Manoon Leechawengwongs; Therdsak Prammananan; Sarinya Jaitrong; Pamaree Billamas; Nampueng Makhao; Nongnard Thamnongdee; Arirat Thanormchat; Arisa Phurattanakornkul; Somcharn Rattanarangsee; Chate Ratanajaraya; Areeya Disratthakit; Angkana Chaiprasert
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

3.  Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.

Authors:  Dorothee Heemskerk; Jeremy Day; Tran Thi Hong Chau; Nguyen Huy Dung; Nguyen Thi Bich Yen; Nguyen Duc Bang; Laura Merson; Piero Olliaro; Thomas Pouplin; Maxine Caws; Marcel Wolbers; Jeremy Farrar
Journal:  Trials       Date:  2011-02-02       Impact factor: 2.279

4.  Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence.

Authors:  Nuria Andreu; Taryn Fletcher; Nitya Krishnan; Siouxsie Wiles; Brian D Robertson
Journal:  J Antimicrob Chemother       Date:  2011-11-17       Impact factor: 5.790

5.  Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach.

Authors:  Elsje Pienaar; Jansy Sarathy; Brendan Prideaux; Jillian Dietzold; Véronique Dartois; Denise E Kirschner; Jennifer J Linderman
Journal:  PLoS Comput Biol       Date:  2017-08-17       Impact factor: 4.475

6.  Functionalization of 3-chloroformylcoumarin to coumarin Schiff bases using reusable catalyst: an approach to molecular docking and biological studies.

Authors:  Suresh S Kumbar; Kallappa M Hosamani; Gangadhar C Gouripur; Shrinivas D Joshi
Journal:  R Soc Open Sci       Date:  2018-05-02       Impact factor: 2.963

7.  Sitafloxacin Expresses Potent Anti-Mycobacterium abscessus Activity.

Authors:  Siyuan He; Qi Guo; Lan Zhao; Liyun Xu; Junsheng Fan; Wenye Wu; Zhemin Zhang; Bing Li; Haiqing Chu
Journal:  Front Microbiol       Date:  2022-01-06       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.